GET DAILY SIGNALSTenaya Therapeutics (TNYA) Declines -32% Over 30 Days on Clinical Hold and Reverse Split Concerns
Key Takeaways
- Tenaya Therapeutics (TNYA) fell roughly 32% over the last 30 days, declining from about $0.57 to near $0.38 per share.
- The selloff was driven primarily by a clinical hold on the TN-201 (MyPEAK-1) trial and a proposed reverse stock split.
- Nasdaq minimum bid price compliance concerns, with shares trading below $1.00, compounded investor anxiety.
- A positive FDA Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 was overshadowed by the negative news.
- Third-quarter 2026 results beat consensus estimates but were not enough to reverse bearish sentiment.
- Management reiterated a cash runway into the fourth quarter of 2027, with about $66.8 million in cash and equivalents as of September 30, 2026.
Company Background and Pipeline Focus
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, that develops potentially curative treatments for heart disease. Its main efforts center on cardiac gene therapies, including TN-201, an AAV9-based candidate for MYBPC3-associated hypertrophic cardiomyopathy; TN-401, an AAV9-based therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; and TN-301, a small-molecule HDAC6 inhibitor for heart failure with preserved ejection fraction. The firm also maintains a research collaboration with Alnylam Pharmaceuticals (ALNY) that could generate up to roughly $1.13 billion in milestone payments. As a pre-revenue company, its valuation hinges on clinical and regulatory progress, so investors monitor pipeline updates and cash position closely. I also checked comparable names using Tickeron’s AI Screener to put the valuation context in perspective.
Recent Stock Price Movement: 30 Days and Quarter
Over the last 30 days, TNYA shares declined approximately 32%, moving from a closing price near $0.57 down to roughly $0.38. The steepest single-session drop came in mid-October on volume above 12 million shares. Over the broader three-month window the stock has fallen about 49%, sliding from the low-$0.70s to current levels. This has left shares near the bottom of their 52-week range and below the $1.00 mark, adding technical and compliance pressure.
Key Drivers Behind the 30-Day Decline
The drop stemmed mainly from company-specific regulatory and structural issues rather than sector-wide pressure. In early October the company reported that the MyPEAK-1 Phase 1b/2 trial of TN-201 had been placed on clinical hold by the FDA. Management indicated it is preparing a protocol amendment to standardize monitoring and immunosuppression, and it believes long-term data milestones remain on track, yet the added uncertainty weighed on sentiment. Around the same period Tenaya filed a preliminary proxy seeking approval for a reverse stock split in the 1-for-10 to 1-for-25 range. This ties directly to Nasdaq listing rules after a minimum-bid-price notice in January 2026 and a transfer to the Capital Market with compliance through January 2027. These factors amplified worries about dilution and delisting risk. They also overshadowed a clear positive: the FDA granted RMAT designation to TN-401 in mid-September based on interim RIDGE-1 data showing reduced arrhythmia burden. Third-quarter 2026 results beat estimates as well, with an EPS loss of $0.08 versus a roughly $0.10 consensus and collaboration revenue of $1.7 million versus about $0.8 million expected. From what I see, the positive developments were simply not enough to shift the prevailing cautious tone.
Broader Quarter-Long Pressures
The multi-month weakness reflects regulatory setbacks, listing-compliance concerns, and ongoing cash burn typical of pre-revenue biotechs. A second-quarter 2026 loss that included a non-cash manufacturing-facility impairment charge had already pressured sentiment, and the TN-201 clinical hold extended uncertainty into the fall. The reverse-split proposal crystallized fears tied to the sub-$1.00 share price. Even supportive pipeline news such as the RMAT designation for TN-401 and a bolstered cash position partly supported by the Alnylam collaboration failed to offset the risk-averse stance toward this small-cap clinical-stage name.
Factors to Watch Going Forward
Several items should shape the outlook for TNYA. The December 2026 special meeting outcome on the reverse stock split and any Nasdaq compliance updates will draw attention. Resolution of the TN-201 clinical hold and further data or regulatory updates on TN-201, TN-401, and TN-301 are expected in the fourth quarter of 2026. Capital management will stay important given the need to fund the pipeline. Analyst consensus remains a Strong Buy with average price targets well above current levels, though some firms have trimmed targets. I’m watching this closely because these milestones will likely determine near-term direction.
Using AI Tools in My Research Process
I regularly turn to Tickeron’s AI Trading Bots when evaluating how automated strategies perform across volatile names like TNYA. The platform lets me compare different risk profiles and timeframes side by side, which helps round out traditional fundamental analysis without replacing it. For anyone interested in data-driven ideas, the AI Trading Bots section offers a straightforward way to explore those options.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
TNYA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 35 cases where TNYA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Indicator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 61 cases where TNYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TNYA just turned positive on October 28, 2026. Looking at past instances where TNYA's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +24.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNYA advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 73 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (3.498). P/E Ratio (-0.706) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement